Skip to main content
. 2021 Oct 1;27(1):213–223. doi: 10.1007/s10147-021-02033-4

Table 3.

TEAEs by CTCAE grade (safety analysis set; n = 16)

Preferred terma All grade, n (%) Grade ≥ 3, n (%)
Pyrexia 14 (87.5) 2 (12.5)
Lymphopeniab 13 (81.3) 13 (81.3)
Neutropeniac 13 (81.3) 13 (81.3)
Thrombocytopeniad 12 (75.0) 10 (62.5)
Leukopeniae 9 (56.3) 9 (56.3)
Decreased appetite 9 (56.3) 4 (25.0)
Diarrhea 8 (50.0) 3 (18.8)
Nausea 8 (50.0) 0 (0.0)
Febrile neutropenia 7 (43.8) 7 (43.8)
Anemia 7 (43.8) 5 (31.3)
Alanine aminotransferase increased 7 (43.8) 1 (6.3)
Aspartate aminotransferase increased 7 (43.8) 1 (6.3)
Malaise 6 (37.5) 0 (0.0)
Headache 5 (31.3) 0 (0.0)
Hypoxia 4 (25.0) 1 (6.3)
Hypophosphatemia 3 (18.8) 3 (18.8)
Hypogammaglobulinemia 3 (18.8) 2 (12.5)
Hyponatremia 3 (18.8) 1 (6.3)
Hypotension 3 (18.8) 1 (6.3)
Vomiting 3 (18.8) 0 (0.0)
Upper respiratory tract infection 3 (18.8) 0 (0.0)
Insomnia 3 (18.8) 0 (0.0)
Nasopharyngitis 3 (18.8) 0 (0.0)

CTCAE Version 4.03. TEAEs (all grade) that occurred in ≥ 3 patients are listed

CTCAE Common Terminology Criteria for Adverse Events, MedDRA Medical Dictionary for Regulatory Activities, TEAE treatment-emergent adverse event

aCoded per MedDRA version 21.0

bLymphopenia includes lymphopenia and lymphocyte count decreased

cNeutropenia includes neutropenia and neutrophil count decreased

dThrombocytopenia includes thrombocytopenia and platelet count decreased

eLeukopenia includes leukopenia and white blood cell count decreased